Clinical trial Recruiting at 12 sites Phase 3 Interventional Ages 18 and up

Rifampicin-containing regimens for Cutibacterium acnes prosthetic joint infections

Official title: Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections

Run by Centre Hospitalier Universitaire de Nice · NCT05902221 · Data updated 2026-11-12

This trial tests whether adding rifampicin to amoxicillin or moxifloxacin can improve outcomes for adults with C. acnes prosthetic joint infections treated with one- or two-stage revisions.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment235 (estimated)
SponsorCentre Hospitalier Universitaire de Nice
Academic / other
Locations13 sites (Annecy and 12 other locations)
StatusRecruiting
StartedMay 2, 2024
Main results expectedMay 2028
Study endsMay 2028
Registry record updatedJune 22, 2026
Trial IDNCT05902221 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18 years) with monomicrobial, rifampicin-susceptible C. acnes infection of a hip, knee, or shoulder prosthesis treated with single-stage or two-stage revision.

Probably not a fit

Patients with mixed infections, rifampicin-resistant C. acnes, non-surgical management, or infections not suitable for the study regimens may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 interventional study examines treatment outcomes for prosthetic joint infections caused by Cutibacterium acnes. Participants must have a rifampicin-susceptible, monomicrobial C. acnes infection in a hip, knee, or shoulder prosthesis and be managed with a single-stage or two-stage revision. The interventions compare amoxicillin or moxifloxacin alone versus the same antibiotic regimen plus rifampicin, aiming to overcome biofilm-related challenges. Outcomes focus on treatment success in the context of biofilm-associated infection and antibiotic susceptibility. The study is conducted across multiple French sites with a lead sponsor at CHU Nice.

Why it matters

Potential benefit: If successful, the regimen including rifampicin could improve infection cure rates and reduce recurrence in C. acnes PJIs.

How similar studies have gone: Previous work suggests rifampicin can enhance outcomes for biofilm-associated infections, but data in C. acnes PJI are limited and this approach is being tested in a randomized, controlled setting.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age: \> or =18 years old;
* Monomicrobial, rifampicin susceptible Cutibacterium acnes late total knee arthroplasty (TKA) or hip arthroplasty (total, THA or hemiarthroplasty, HH) or shoulder arthroplasty (total, TSA or hemiarthroplasty, SH) infection treated surgically with single-stage or two-stage revision;
* Isolation of C. acnes on two distinct per-operative samples collected during the single-stage or the two-stage revision
* Based on the antimicrobial susceptibility test of the C. acnes and the medical history of the patient, the PJI can be treated with amoxicillin or moxifloxacin;
* Women considered of childbearing potential (WOCBP) requires use of a highly effective contraceptive measure as intrauterine device (IUD), intrauterine hormone-releasing system (IUS), documented bilateral tubal occlusion, documented vasectomised partner, sexual abstinence. Contraception should be maintained during treatment and until the end of relevant systemic exposure.

Exclusion Criteria:

* Contraindication to Rifampicin (included ongoing treatment contraindicated with rifampicin)
* Contraindication to Amoxicillin AND moxifloxacin (included ongoing treatment contraindicated with these medicines)
* Empirical antibiotic treatment not administered during the 24 hours following revision surgery;
* Inactive empirical antibiotic treatment following surgery according to the AST of the bacteria;
* disease-modifying treatment incompatible with the inducer effect of rifampicin
* Liver cirrhosis;
* Pregnancy: a pregnancy blood test will be performed on all women of childbearing age. The results will be sent to the patient by the doctor of their choice;
* Porphyria;
* Renal insufficiency with GFR \< 30ml/min/1.73 m2 (CKD-EPI);

Where it's running

  • CH Annecy Genevois
    Annecy, France
    Recruiting
  • CHU de BORDEAUX
    Bordeaux, France
    Recruiting
  • Hôpital Ambroise Paré
    Boulogne, France
    Recruiting
  • Hcl
    Lyon, France
    Recruiting
  • CHU de MONTPELLIER
    Montpellier, France
    Recruiting
  • CHU de Nantes
    Nantes, France
    Recruiting
Show 7 more locations
  • CHU de NICE
    Nice, France
    Recruiting
  • Dianonesses croix saint simon
    Paris, France
    Recruiting
  • CHU de Rennes
    Rennes, France
    Recruiting
  • CHU Toulouse
    Toulouse, France
    Recruiting
  • Ch Tourcoing
    Tourcoing, France
    Recruiting
  • CHRU Tours
    Tours, France
    Recruiting
  • Ap-Hm
    Marseille, France
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.